Xenon Pharmaceuticals (XENE) Cash from Operations (2016 - 2025)
Historic Cash from Operations for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to -$71.8 million.
- Xenon Pharmaceuticals' Cash from Operations fell 4447.2% to -$71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$252.0 million, marking a year-over-year decrease of 5518.12%. This contributed to the annual value of -$181.4 million for FY2024, which is 2003.61% down from last year.
- According to the latest figures from Q3 2025, Xenon Pharmaceuticals' Cash from Operations is -$71.8 million, which was down 4447.2% from -$64.2 million recorded in Q2 2025.
- In the past 5 years, Xenon Pharmaceuticals' Cash from Operations ranged from a high of -$13.1 million in Q2 2021 and a low of -$71.8 million during Q3 2025
- Its 5-year average for Cash from Operations is -$36.9 million, with a median of -$34.4 million in 2023.
- As far as peak fluctuations go, Xenon Pharmaceuticals' Cash from Operations soared by 1101.02% in 2022, and later tumbled by 10619.22% in 2025.
- Xenon Pharmaceuticals' Cash from Operations (Quarter) stood at -$20.7 million in 2021, then tumbled by 70.59% to -$35.3 million in 2022, then fell by 0.2% to -$35.4 million in 2023, then crashed by 53.63% to -$54.4 million in 2024, then tumbled by 31.93% to -$71.8 million in 2025.
- Its Cash from Operations was -$71.8 million in Q3 2025, compared to -$64.2 million in Q2 2025 and -$61.7 million in Q1 2025.